Literature DB >> 10560657

Application of the National Institute on Aging (NIA)-Reagan Institute criteria for the neuropathological diagnosis of Alzheimer disease.

K L Newell1, B T Hyman, J H Growdon, E T Hedley-Whyte.   

Abstract

The Khachaturian criteria and the Consortium to Establish a Registry for Alzheimer Disease (CERAD) criteria for the neuropathological assessment of Alzheimer disease (AD) emphasize senile or neuritic plaques, age, and clinical history. A new scheme stressing topographic staging of neurofibrillary changes in addition to neuritic plaques has been proposed by the National Institute on Aging (NIA)-Reagan Institute Consensus Conference. This scheme assigns cases to high, intermediate, or low likelihood categories that the dementia is due to AD. We applied this method to 84 brains from subjects with clinical and neuropathological diagnoses of AD (n = 33), non-AD dementing illnesses (n = 34), including dementia with Lewy bodies (DLB) and progressive supranuclear palsy (PSP), and no neurological disease (n = 17). We also used Khachaturian and CERAD criteria. Neurofibrillary tangle and neuropil thread densities were assessed on 6-micrometer-thick modified Bielschowsky-stained paraffin sections from entorhinal-perirhinal cortex, CA1 of hippocampus, and neocortex including inferior temporal, visual association, and primary visual cortices. Each case was assigned a Braak and Braak stage. Using the NIA-Reagan criteria, we found excellent agreement between clinical history of AD dementia and brains assigned to the high likelihood category that dementia was due to AD. Among brains diagnosed neuropathologically with other degenerative diseases, NIA-Reagan criteria were more conservative than previous criteria, and these cases were likely to be categorized as intermediate or low likelihood that dementia was due to AD. All brains from nondemented subjects were assigned to the low (81%) or intermediate (19%) categories. In summary, we found good correlation between the NIA-Reagan criteria and clinical dementia, and there was generally good agreement between these criteria and existing neuropathological methods, Khachaturian and CERAD, in diagnosing AD. In studying several other neurodegenerative diseases, such as DLB, which shows neuropathological and clinical overlap with AD, the staging of neurofibrillary changes offered potential diagnostic refinement.

Entities:  

Mesh:

Year:  1999        PMID: 10560657     DOI: 10.1097/00005072-199911000-00004

Source DB:  PubMed          Journal:  J Neuropathol Exp Neurol        ISSN: 0022-3069            Impact factor:   3.685


  99 in total

1.  Gene expression profiling in fetal, aged, and Alzheimer hippocampus: a continuum of stress-related signaling.

Authors:  Walter J Lukiw
Journal:  Neurochem Res       Date:  2004-06       Impact factor: 3.996

2.  Understanding dementia prevalence among centenarians.

Authors:  Leonard W Poon; John L Woodard; L Stephen Miller; Robert Green; Marla Gearing; Adam Davey; Jonathan Arnold; Peter Martin; Ilene C Siegler; Lusine Nahapetyan; Young Sek Kim; William Markesbery
Journal:  J Gerontol A Biol Sci Med Sci       Date:  2012-03-01       Impact factor: 6.053

3.  Accuracy of the clinical diagnosis of Alzheimer disease at National Institute on Aging Alzheimer Disease Centers, 2005-2010.

Authors:  Thomas G Beach; Sarah E Monsell; Leslie E Phillips; Walter Kukull
Journal:  J Neuropathol Exp Neurol       Date:  2012-04       Impact factor: 3.685

4.  Pattern separation and pattern completion in Alzheimer's disease: evidence of rapid forgetting in amnestic mild cognitive impairment.

Authors:  Brandon A Ally; Erin P Hussey; Philip C Ko; Robert J Molitor
Journal:  Hippocampus       Date:  2013-08-14       Impact factor: 3.899

5.  Expression profiling of precuneus layer III cathepsin D-immunopositive pyramidal neurons in mild cognitive impairment and Alzheimer's disease: Evidence for neuronal signaling vulnerability.

Authors:  Bin He; Sylvia E Perez; Sang H Lee; Stephen D Ginsberg; Michael Malek-Ahmadi; Elliott J Mufson
Journal:  J Comp Neurol       Date:  2020-05-05       Impact factor: 3.215

6.  MMSE scores decline at a greater rate in frontotemporal degeneration than in AD.

Authors:  Tiffany W Chow; Linda S Hynan; Anne M Lipton
Journal:  Dement Geriatr Cogn Disord       Date:  2006-08-07       Impact factor: 2.959

7.  Hippocampal proNGF signaling pathways and β-amyloid levels in mild cognitive impairment and Alzheimer disease.

Authors:  Elliott J Mufson; Bin He; Muhammad Nadeem; Sylvia E Perez; Scott E Counts; Sue Leurgans; Jason Fritz; James Lah; Stephen D Ginsberg; Joanne Wuu; Stephen W Scheff
Journal:  J Neuropathol Exp Neurol       Date:  2012-11       Impact factor: 3.685

8.  Increased expression of toll-like receptor 3, an anti-viral signaling molecule, and related genes in Alzheimer's disease brains.

Authors:  Douglas G Walker; Tiffany M Tang; Lih-Fen Lue
Journal:  Exp Neurol       Date:  2018-08-01       Impact factor: 5.330

Review 9.  Using Pittsburgh Compound B for in vivo PET imaging of fibrillar amyloid-beta.

Authors:  Ann D Cohen; Gil D Rabinovici; Chester A Mathis; William J Jagust; William E Klunk; Milos D Ikonomovic
Journal:  Adv Pharmacol       Date:  2012

10.  Focal atrophy on MRI and neuropathologic classification of dementia with Lewy bodies.

Authors:  Kejal Kantarci; Tanis J Ferman; Bradley F Boeve; Stephen D Weigand; Scott Przybelski; Prashanthi Vemuri; Melissa E Murray; Melissa M Murray; Matthew L Senjem; Glenn E Smith; David S Knopman; Ronald C Petersen; Clifford R Jack; Joseph E Parisi; Dennis W Dickson
Journal:  Neurology       Date:  2012-07-25       Impact factor: 9.910

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.